Background: Major depressive disorder (MDD) is linked with a 2‐fold higher risk of developing Alzheimer’s disease (AD), yet the mechanisms behind this association are unclear and are confounded by psychotropic drug use. We, therefore, aimed to investigate AD‐related transcriptional changes in post‐mortem MDD brains without symptoms of dementia and their matched controls, taking into consideration psychotropic medication‐use history.Method: NanoString Technologies nCounter® analysis using their Alzheimer’s Disease Panel (770 genes) was performed on mRNA extracts from post‐mortem prefrontal cortex tissue of suicide victims with ante‐mortem MDD diagnoses, including 6 drug‐free cases and 6 with a previous history of psychotropic medication use whose serological screening included antidepressants, antipsychotics, benzodiazepines. The results were compared with 12 age and sex matched non‐neurological controls. The data was analysed using nSolver advanced analysis software and built‐in statistical analyses.Result: When comparing total MDD cases vs. healthy controls, genes involved in lipid metabolism and myelination (e.g., CDK18, 1.9‐fold; ABCA2, 1.91) and cytokines (CSF1, 1.93; LIFR, 1.26) were found upregulated in MDD, whereas the most downregulated genes included neurotransmitter synthesis and storage (RAB3A, 0.79), neurotransmitter release (CAMK4, 0.741) and vesicle trafficking (NPTX2, 0.519). In a comparison of MDD drug‐free group vs. MDD with drug use group, patients with drug use displayed upregulations of genes related to lipid metabolism and myelination (NKX6‐2, 4.5) autophagy (ABCA2, 3.32) and cytokines (CSF1, 2.53; LIFR 1.34), whereas drug‐free patients showed higher expression of neurotransmitter release (GRIA3, 0.742), transcription‐splicing (DDX42, 0.807) and trophic factor (NTRK2, 0.732) genes. TSPO, a gene related to microglial activation, was the most significantly upregulated gene (3.23‐fold) in MDD patients taking psychotropic medications.Conclusion: The study provides evidence that alterations in pathways involving neuroinflammation, metabolism and neurotransmission in the brains of MDD patients might provide the link with AD and highlights the need to investigate the role of psychotropic medications in modulating AD‐related pathways.